Evaluation of potential prognostic significance of JUNB in human prostate cancer: a bioinformatic and histopathological study.

IF 3 Q3 PATHOLOGY

Journal of Pathology and Translational Medicine Pub Date : 2025-09-01 Epub Date: 2025-09-08 DOI:10.4132/jptm.2025.06.06

Noha R Noufal, Einas M Yousef, Mohamed Taha

{"title":"Evaluation of potential prognostic significance of JUNB in human prostate cancer: a bioinformatic and histopathological study.","authors":"Noha R Noufal, Einas M Yousef, Mohamed Taha","doi":"10.4132/jptm.2025.06.06","DOIUrl":null,"url":null,"abstract":"Background: Prostate cancer is one of the most common malignancies in males worldwide. Serum prostate-specific antigen is a frequently employed biomarker in the diagnosis and risk stratification of prostate cancer; however, it is known for its low predictive accuracy for disease progression. New prognostic biomarkers are needed to distinguish aggressive prostate cancer from low-risk disease. This study aimed to identify and validate potential prognostic biomarkers of prostate cancer.Methods: Two prostate cancer datasets from the Gene Expression Omnibus were analyzed to identify differentially expressed genes between benign prostatic hyperplasia (BPH) and prostatic carcinoma. Immunohistochemistry was used to evaluate the JUNB proto-oncogene, a subunit of the AP-1 transcription factor (JUNB), in 70 prostate cancer patients and 10 BPH samples.Results: Our findings showed that JUNB was significantly enriched in prostate cancer-related pathways and biological processes. JUNB expression was considerably higher in prostatic adenocarcinoma patients than in BPH patients. Regarding JUNB expression in prostate cancer cases, lower levels of JUNB expression were associated with higher grades of prostatic adenocarcinoma. Lower JUNB expression was associated with a higher risk of prostatic adenocarcinoma progression and shorter overall survival.Conclusions: These results suggest that JUNB is a promising prognostic biomarker and a potential tumor suppressor in prostate cancer.","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":" ","pages":"291-305"},"PeriodicalIF":3.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12455463/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pathology and Translational Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4132/jptm.2025.06.06","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Prostate cancer is one of the most common malignancies in males worldwide. Serum prostate-specific antigen is a frequently employed biomarker in the diagnosis and risk stratification of prostate cancer; however, it is known for its low predictive accuracy for disease progression. New prognostic biomarkers are needed to distinguish aggressive prostate cancer from low-risk disease. This study aimed to identify and validate potential prognostic biomarkers of prostate cancer.

Methods: Two prostate cancer datasets from the Gene Expression Omnibus were analyzed to identify differentially expressed genes between benign prostatic hyperplasia (BPH) and prostatic carcinoma. Immunohistochemistry was used to evaluate the JUNB proto-oncogene, a subunit of the AP-1 transcription factor (JUNB), in 70 prostate cancer patients and 10 BPH samples.

Results: Our findings showed that JUNB was significantly enriched in prostate cancer-related pathways and biological processes. JUNB expression was considerably higher in prostatic adenocarcinoma patients than in BPH patients. Regarding JUNB expression in prostate cancer cases, lower levels of JUNB expression were associated with higher grades of prostatic adenocarcinoma. Lower JUNB expression was associated with a higher risk of prostatic adenocarcinoma progression and shorter overall survival.

Conclusions: These results suggest that JUNB is a promising prognostic biomarker and a potential tumor suppressor in prostate cancer.

查看原文本刊更多论文

评价JUNB在人类前列腺癌中的潜在预后意义：一项生物信息学和组织病理学研究。

背景：前列腺癌是全球男性最常见的恶性肿瘤之一。血清前列腺特异性抗原是前列腺癌诊断和危险分层中常用的生物标志物；然而，众所周知，它对疾病进展的预测准确性较低。需要新的预后生物标志物来区分侵袭性前列腺癌和低风险疾病。本研究旨在识别和验证前列腺癌潜在的预后生物标志物。方法：分析来自基因表达综合数据库的两个前列腺癌数据集，以确定良性前列腺增生（BPH）和前列腺癌之间的差异表达基因。应用免疫组化技术对70例前列腺癌患者和10例BPH样本中的JUNB原癌基因（AP-1转录因子（JUNB）的一个亚基）进行了评估。结果：我们的研究结果表明JUNB在前列腺癌相关通路和生物学过程中显著富集。JUNB在前列腺腺癌患者中的表达明显高于BPH患者。关于前列腺癌病例中JUNB的表达，低水平的JUNB表达与高级别的前列腺腺癌相关。较低的JUNB表达与前列腺腺癌进展的高风险和较短的总生存期相关。结论：这些结果表明JUNB是一种有前景的预后生物标志物和潜在的前列腺癌肿瘤抑制因子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pathology and Translational Medicine PATHOLOGY-

CiteScore

5.00

自引率

4.20%

发文量

审稿时长

14 weeks

期刊介绍： The Journal of Pathology and Translational Medicine is an open venue for the rapid publication of major achievements in various fields of pathology, cytopathology, and biomedical and translational research. The Journal aims to share new insights into the molecular and cellular mechanisms of human diseases and to report major advances in both experimental and clinical medicine, with a particular emphasis on translational research. The investigations of human cells and tissues using high-dimensional biology techniques such as genomics and proteomics will be given a high priority. Articles on stem cell biology are also welcome. The categories of manuscript include original articles, review and perspective articles, case studies, brief case reports, and letters to the editor.